Plasmodium falciparum

In 2010, we reviewed the medical records of 314 asymptomatic (defined as patients with no symptoms at the time of consultation) immigrants from sub-Saharan Africa who had settled in Spain, had not traveled to their countries of origin since arrival, and had been examined at the Tropical Medicine Unit (TMU) of the Ramon y Cajal Hospital in Madrid during the previous 5 years.

This review aims to discuss the computational approaches used till date to construct a malaria protein interaction network and to catalog the functional predictions and biological inferences made from analysis of the PPI network.

We report the identification of a parasite protein, designated PfSET10, which localizes exclusively to the perinuclear active var gene expression site.

Our reverse genetics data demonstrate that each of the two regulatory PfCK2 subunits is required for completion of the asexual erythrocytic cycle.

Plasmodium falciparum blood-stage antigens such as merozoite surface protein 1 (MSP-1), apical membrane antigen 1 (AMA-1), and the 175-kDa erythrocyte binding antigen (EBA-175) are considered important targets of naturally acquired immunity to malaria.

Over the past decade, advances in proteomic and mass spectrometry techniques and the sequencing of the Plasmodium falciparum genome have led to an increasing number of studies regarding the parasite proteome.

For decades, drug resistance has been the major obstacle in the fight against malaria, and the search for new drugs together with the combination therapy constitutes the major approach in responding to this situation.

PfEMP1 proteins comprise a family of variant antigens that appear on the surface of P. falciparum-infected erythrocytes and bind to multiple host receptors.

Plasmodium falciparum serine repeat antigen 5 (SERA5) is a target for both drug and vaccine intervention against malaria.

The effects of AS&AQ on haematologic parameters were not different from those of other anti-malarial treatments used in sub-Saharan Africa.